http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

丝裂霉素葡聚糖微球的研究

魏树礼, 孙贻春, 张敬石, 谭惟薇, 谢敬霞, 李选, 朱建纲   

  1. 1. 北京医科大学药学院;
    2. 北京医科大学第三医院 北京 100083

  • 收稿日期:1991-10-14 修回日期:1992-03-10 出版日期:1992-06-15 发布日期:1992-06-15

Studies on Mitomycin C Dextran-microspheres

Shu-Li Wei, Yi-Chun Sun, Jing-Shi Zhang, Wei-Wei Tan, Jing-Xia Xie, Xuan Li, Jian-Gang Zhu

  

  1. 1. School of Pharmaceutical Sciences; Beijing Medical University; Beijing 100083;
    2. The Third Hospital; Beijing Medical University Beijing 100083

  • Received:1991-10-14 Revised:1992-03-10 Online:1992-06-15 Published:1992-06-15

摘要:

本文报告了丝裂霉素葡聚糖微球的制备与性质, 也研究了丝裂霉素葡聚糖微球(简称(MMC-DMS)在狗体内的药物动力学特征和栓塞效果。微球的平均粒径为75±19 μm, MMC含量为5%。在体外实验中, 药物释放速度证明微球有缓释的性质。丝裂霉素葡聚糖微球与常规丝裂霉素通过导管分别输入狗的肝动脉内进行栓塞。用高效液相色谱(HPLC)法测定血药浓度, 结果表明常规丝裂霉素峰浓度比MMC-DMS1.6倍。血管造影显示肝的外周血管显著减少。组织病理学检查表明微球嵌入肝动脉内并在栓塞部分显示结节性坏死。MMC-DMS 在临床上试用于100例患肝癌的病人, 肝动脉栓塞后病人瘤块缩小, 症状改善, 存活期延长。这些结果提示丝裂霉素葡聚糖微球是治疗肝癌很有用的栓塞剂, 将有利于增强癌症化疗效果减少全身毒副反应。

关键词: 丝裂霉素 C, 丝裂霉素葡聚糖微球, 肝动脉栓塞, 肝癌

Abstract:

In this paper, the preparation and properties of mitomycin C dextran-microspheres(MMC-DMS)were reported. The characteristics of pharmacokinetics and embolization effects of MMC-DMS in vivo were studied in dogs. The average diameter of the microspheres was 75±19 μm and the content was 5% of MMC. In vitro experiment, the release rate of drug demonstrated that the microspheres had sustained-release properties. The microspheres and conventional MMC were infused into the hepatic artery of dogs through a catheter for embolization, respectively. The plasma concentration of MMC was determined by HPLC. Results showed that the peak concentration of conventional MMC was 2.6 times as much as MMC-DMS. Angiograms revealed that peripheral blood vessels decreased obviously in liver. The histopathologic examination showed that the microspheres lodged in the hepatic artery and displayed nodular necrosis in the embolized segment. The MMC-DMS were used in clinical trial in 100 patients with hepatic cancer. The tumor reduction and improvement of symptoms in patients were observed after hepatic arterial embolization. The survival duration was prolonged. Results showed that the MMC-DMS is a promising embolic agent for treatment of hepatic cancer. It could aid in the use of intensive chemotherapy with minimum systemic side effect.

Key words: Mitomycin C, Mitomycin C, dextran-microspheres, Hepatic arterial embolization, Hepatic cancer

Supporting: